Lucas Bethge

USPTO Granted Patents = 12 (Patent Applications = 10)

CIPO Patents = 4 (Patent Applications = 6)

EPO Patents = 5 (Patent Applications = 24)

Average Co-Inventor Count = 2.9

ph-index = 2

Forward Citations = 20(Granted Patents)

Location History:

Potsdam, DE (2015 - 2024)
Berlin, DE (2021 - 2024)

Company Filing History:

9 out of 37

Silence Therapeutics Gmbh

Humboldt-universität Zu Berlin

patents

Years Active: 2015-2024

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12054717 - Nucleic acids for inhibiting expression of LPA in a cell (2024-08-06),

2. 11987794 - Products and compositions (2024-05-21),

3. 11873489 - Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages (2024-01-16),

4. 11753642 - Nucleic acids for inhibiting expression of C3 in a cell (2023-09-12),

5. 11560563 - SiRNAs with vinylphosphonate at the 5' end of the antisense strand (2023-01-24),

6. 11499153 - Nucleic acids for inhibiting expression of LPA in a cell (2022-11-15),

7. 11459352 - Method for polyalkoxylation of nucleic acids that enables recovery and reuse of excess polyalkoxylation reagent (2022-10-04),

8. 11414660 - Products and compositions (2022-08-16),

9. 11319537 - Nucleic acids for inhibiting expression of LPA in a cell (2022-05-03),

10. 11174483 - Products and compositions (2021-11-16),

11. 10513536 - Methods for the preparation of a polyalkoxylated nucleic acid molecule (2019-12-24),

12. 9206218 - Probes comprising fluorescent artificial nucleobases and use thereof for detection of single base alteration (2015-12-08),

Title: Innovations and Contributions of Inventor Lucas Bethge

Introduction

Lucas Bethge is a renowned inventor based in Potsdam, Germany. With an impressive portfolio of 12 patents, he has made significant contributions to the field of biomedical research, particularly in the area of cardiovascular disease.

Latest Patents

Among his latest innovations, Lucas has developed two notable patents. The first, titled "Nucleic acids for inhibiting the expression of LPA in a cell," focuses on nucleic acid products that interfere with LPA gene expression. This invention offers potential treatment options for preventing or reducing the risk of cardiovascular diseases such as coronary heart disease, aortic stenosis, and stroke, as well as disorders linked to elevated Lp(a)-containing particles. The second patent, simply referred to as "Products and compositions," pertains to nucleic acid products that inhibit target gene expression, showcasing therapeutic uses that can have wide-ranging implications in medicine.

Career Highlights

Throughout his career, Lucas has made strides at notable companies in the biomedical sector. He has been involved with Silence Therapeutics GmbH and Noxxon Pharma AG, where he applied his expertise to advance innovative treatments. His work has not only emphasized the importance of gene expression but has also opened new avenues for research and development in genetics and therapeutics.

Collaborations

Lucas has collaborated with talented coworkers such as Adrien Weingärtner and Judith Hauptmann. These collaborations have further enriched his research, enabling the cross-pollination of ideas and the enhancement of scientific outcomes within their respective projects.

Conclusion

Lucas Bethge's contributions through his inventions represent a significant advancement in the field of biomedical research. His dedication to developing therapeutics for cardiovascular diseases demonstrates his commitment to improving health outcomes. As an inventor with a solid patent portfolio, Lucas continues to be a prominent figure in innovation within the scientific community.

This text is generated by artificial intelligence and may not be accurate.